<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertrophic cardiomyopathy in children: Clinical manifestations and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertrophic cardiomyopathy in children: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertrophic cardiomyopathy in children: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas D Ryan, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Maron, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John K Triedman, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1508167812"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypertrophic cardiomyopathy (HCM) is one of the most common forms of inherited cardiomyopathy in both adults and children. It is characterized by hypertrophy of the left ventricle (LV)  (<a class="graphic graphic_diagnosticimage graphicRef110321 graphicRef110322" href="/z/d/graphic/110321.html" rel="external">image 1A-B</a> and <a class="graphic graphic_diagnosticimage graphicRef110280 graphicRef110312" href="/z/d/graphic/110280.html" rel="external">image 2A-B</a>). The disease course is highly variable, but it is well recognized that there is an increased risk of morbidity and sudden cardiac death (SCD). (See  <a class="medical medical_review" href="/z/d/html/85989.html" rel="external">"Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in children"</a>.)</p><p>This topic will review the epidemiology, clinical manifestations, and diagnosis of HCM in children. The management and prognosis of pediatric HCM and other related topics are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/110392.html" rel="external">"Hypertrophic cardiomyopathy in children: Management and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/85989.html" rel="external">"Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4916.html" rel="external">"Hypertrophic cardiomyopathy: Natural history and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4950.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients without outflow tract obstruction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4920.html" rel="external">"Hypertrophic cardiomyopathy: Management of patients with outflow tract obstruction"</a>.)</p><p></p><p class="headingAnchor" id="H1517651679"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The terms HCM and left ventricular hypertrophy (LVH) are applied broadly to a number of different clinical presentations:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetically determined HCM</strong> – Genetically determined HCM includes sarcomeric and nonsarcomeric (or syndromic) HCM; the term specifically excludes LVH due to secondary influences (eg, athletic training, hypertension, other systemic illnesses).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sarcomeric HCM</strong> – Sarcomeric HCM (sometimes referred to as "true HCM") is a condition caused by pathologic variants in genes encoding sarcomeric proteins  (<a class="graphic graphic_figure graphicRef90769" href="/z/d/graphic/90769.html" rel="external">figure 1</a>). (See <a class="local">'Genetics'</a> below and  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing", section on 'Sarcomeric gene mutations causing HCM'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsarcomeric (syndromic) HCM</strong> –<strong> </strong>Increasingly, variants in nonsarcomeric genes encoding proteins with a wide range of functions have been shown to cause HCM [<a href="#rid1">1</a>]. There are a number of genetic syndromes and neuromuscular disorders that present with morphologic characteristics similar to sarcomeric HCM (sometimes called "HCM phenocopies"). These include inborn errors of metabolism, multiple congenital anomaly syndromes (eg, Noonan syndrome), mitochondrial disorders, and neuromuscular disorders  (<a class="graphic graphic_table graphicRef107815" href="/z/d/graphic/107815.html" rel="external">table 1</a>). The most common of these syndromes is <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F163950&amp;token=87jLzclRwWxNoI%2BQq5Gg75WTlw57WTDc8sLliazyQDoUAOAReoMjxfwtLLcj6CQ0&amp;TOPIC_ID=4951" target="_blank">Noonan syndrome</a>, with other examples including <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F300257&amp;token=87jLzclRwWxNoI%2BQq5Gg7xh7CQmDfKP7VLBrAQpd%2Bl64PCI7jJzYhrpF3PxWs%2BQd&amp;TOPIC_ID=4951" target="_blank">Danon disease</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F229300&amp;token=87jLzclRwWxNoI%2BQq5Gg7zxBJ4T5zZKwZDQQRmDYR2zfKb8Zma%2BkhZb7D9%2B4Uwz%2F&amp;TOPIC_ID=4951" target="_blank">Friedreich ataxia</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F301500&amp;token=87jLzclRwWxNoI%2BQq5Gg7yf2rrVZQZLAC5%2FG3vhTVX155Tb42F3o8HNnG%2Btl9mtB&amp;TOPIC_ID=4951" target="_blank">Fabry disease</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F151100&amp;token=87jLzclRwWxNoI%2BQq5Gg7wg%2Fe%2F754umOQl0hZXMu97WC%2BJZ9bBvA8NCbJ2FCjU%2Bz&amp;TOPIC_ID=4951" target="_blank">LEOPARD syndrome</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F232300&amp;token=87jLzclRwWxNoI%2BQq5Gg74kl%2FZLavhyFLzr6mgsxGctWUeGMpcK6DB9K74JFZXtL&amp;TOPIC_ID=4951" target="_blank">Pompe disease</a>, and mitochondrial diseases [<a href="#rid2">2</a>]. Mutations of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F600858&amp;token=87jLzclRwWxNoI%2BQq5Gg79PvDxQ1hsMhh3M8yfFcLXWDV4ACPrtUbW32JS2QTffD&amp;TOPIC_ID=4951" target="_blank"><i>PRKGA2</i></a> are another rare cause of nonsarcomeric HCM.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preclinical HCM</strong> – The term preclinical HCM (also called genotype-positive/phenotype-negative [G+ P-]) describes individuals who are known to carry a pathologic variant in a gene associated with HCM but who lack current clinical evidence of HCM (ie, no LVH on echocardiography). G+ P- individuals are typically identified through cascade testing after a family member is diagnosed with HCM. (See <a class="local">'Evaluation of first-degree relatives'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adaptive or secondary LVH</strong> – Adaptive changes to stimuli such as athletic training or hypertension can occur in pediatric patients; however, LVH resulting from these adaptations is <strong>not</strong> considered HCM. In addition, secondary causes of LVH such as pulmonary parenchymal or vascular disease, endocrine disease (eg, maternal diabetes), rheumatic disease, immunological disease, and cardiotoxic exposures are <strong>not</strong> considered HCM. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p>There is debate over whether syndromic causes of HCM should be included when describing pediatric HCM. The approach to therapy is often the same, though it is worth noting that patients with syndromic causes of HCM are often excluded from studies of medical and implantable cardioverter-defibrillator therapy. In addition, the prognosis is generally worse for syndromic HCM, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/110392.html" rel="external">"Hypertrophic cardiomyopathy in children: Management and prognosis", section on 'Prognosis'</a>.)</p><p>In this topic review, nonsyndromic and syndromic causes of HCM are considered together under the broad term "HCM" unless otherwise specified.</p><p class="headingAnchor" id="H4254758145"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of HCM in the general pediatric population is likely underestimated since many affected children have subclinical disease. Based on data from various pediatric cardiomyopathy registries, the annual incidence of HCM from all causes (including sarcomeric, syndromic forms, and idiopathic) is approximately 0.3 to 0.5 cases per 100,000 children [<a href="#rid3">3-7</a>]. The peak incidence is in infants &lt;1 year old, there is a slight male predominance, and in the US population, prevalence is higher in African American children than in White or Hispanic children. In total, HCM accounts for 25 to 40 percent of all pediatric cardiomyopathy cases [<a href="#rid4">4,5</a>]. In adult populations, the prevalence of HCM is estimated at approximately 1 in 500 persons. (See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Prevalence'</a>.)</p><p class="headingAnchor" id="H1954123854"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>Genes encoding sarcomeric proteins account for the majority of known pathogenic variants in HCM  (<a class="graphic graphic_figure graphicRef90769" href="/z/d/graphic/90769.html" rel="external">figure 1</a>) [<a href="#rid8">8</a>]. Increasingly, variants in nonsarcomeric genes encoding proteins with a wide range of functions have also been shown to cause HCM [<a href="#rid1">1</a>]. Genetic syndromes and neuromuscular disorders that present with morphologic characteristics similar to sarcomeric HCM (sometimes called "HCM phenocopies") are summarized in the table  (<a class="graphic graphic_table graphicRef107815" href="/z/d/graphic/107815.html" rel="external">table 1</a>). These conditions account for approximately 15 to 25 percent of pediatric HCM [<a href="#rid3">3,4,7,9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsyndromic HCM</strong> – In studies of pediatric patients with nonsyndromic HCM who underwent genetic testing, approximately 50 to 70 percent were found to have pathogenic or likely pathogenic variants, mostly in genes encoding sarcomeric proteins  (<a class="graphic graphic_figure graphicRef90769" href="/z/d/graphic/90769.html" rel="external">figure 1</a>) [<a href="#rid10">10-12</a>]. The diagnostic yield of genetic testing varies depending on the specific genes included in the testing panel and whether the child has a family history of cardiomyopathy (the yield is generally higher in children with familial cardiomyopathy) [<a href="#rid10">10,12</a>]. Disease expression among first-degree family members with sarcomeric HCM can be dramatically different [<a href="#rid8">8,13,14</a>].</p><p></p><p class="bulletIndent1">In a study of 337 pediatric patients with nonsyndromic HCM who had disease-causing variants identified through genetic testing, the relative frequencies of genetic variants were as follows [<a href="#rid12">12</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Single variant in a sarcomeric gene – 91 percent (variants in <em>MYBPC3</em> or <em>MYH7</em> accounted for 74 percent)</p><p class="bulletIndent2"><span class="glyph">•</span>Single variant in a nonsarcomeric gene – 4 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Multiple variants identified – 5 percent</p><p></p><p class="bulletIndent1">Approximately 30 to 50 percent of pediatric patients with phenotypically determined HCM will have no identified pathogenic variant (referred to as phenotype-positive/genotype-negative) [<a href="#rid11">11</a>]. In the absence of clinical signs of a syndrome or systemic disease as the underlying cause, the assumption is that such patients are genetically determined with a yet undiscovered mutation or gene. However, simple mendelian inheritance alone is insufficient to explain inheritance patterns, and some nonsarcomeric mutations and genetic polymorphisms are known to work in a polygenic manner [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing", section on 'Renin-angiotensin system polymorphisms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syndromic HCM </strong>– Approximately 15 to 25 percent of children with HCM have underlying genetic syndromes  (<a class="graphic graphic_table graphicRef107815" href="/z/d/graphic/107815.html" rel="external">table 1</a>) [<a href="#rid3">3,4,7,9</a>]. In a report from the from the Pediatric Cardiomyopathy Registry that included 855 children with HCM (nonsyndromic HCM in 75 percent and syndromic in 25 percent), identified causes among patients with syndromic HCM included [<a href="#rid3">3</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple congenital abnormality (MCA) syndromes – MCA syndromes accounted for 9 percent of all HCM cases and 36 percent of syndromic HCM. Noonan syndrome was the most common syndrome, accounting for 78 percent of cases in this category. (See  <a class="medical medical_review" href="/z/d/html/13558.html" rel="external">"Noonan syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inborn errors of metabolism (IEM) – IEMs accounted for 9 percent of all HCM cases and 34 percent of syndromic HCM. Pompe disease was the most common IEM, accounting for 34 percent of cases in this category. (See  <a class="medical medical_review" href="/z/d/html/2905.html" rel="external">"Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuromuscular disorders – Neuromuscular disorders accounted for 7 percent of all HCM cases and 30 percent of syndromic HCM. Friedreich ataxia was the most common neuromuscular disorder, accounting for 88 percent of cases in this category. (See  <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">"Friedreich ataxia"</a>.)</p><p></p><p>Additional details regarding the genetics of HCM are provided separately. (See  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing"</a>.)</p><p class="headingAnchor" id="H3082317211"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical findings associated with HCM can develop in infants and prepubertal children but are more commonly seen in teenagers and young adults following the growth spurt and other changes associated with puberty. Because children with sarcomeric HCM often have no or minor symptoms, affected individuals are frequently diagnosed as a result of family screening, detection of a murmur during routine examination, or the identification of an abnormal electrocardiogram (ECG). Patients with syndromic or systemic disease may be brought to attention as part of screening, but only if providers appreciate the association.</p><p>A small subset of patients will progress to an advanced form of the disease that is characterized by relative LV dilation and wall thinning and systolic dysfunction, the so-called "burned out HCM" phenotype. In a cohort which included both pediatric and adult patients, LV systolic dysfunction (LV ejection fraction [LVEF] &lt;50 percent) has been reported in approximately 5 to 8 percent of patients with HCM [<a href="#rid16">16,17</a>]. This group of patients is at higher risk for atrial fibrillation, stroke, symptomatic heart failure, and SCD [<a href="#rid16">16,17</a>]. Such patients are managed according to the standard approach to patients with heart failure due to systolic dysfunction and may progress to the need for mechanical circulatory support or heart transplantation. (See  <a class="medical medical_review" href="/z/d/html/14520.html" rel="external">"Heart failure in children: Management"</a>.)</p><p class="headingAnchor" id="H3182149042"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>The signs and symptoms of HCM in pediatric patients vary based on age and associated conditions. Many pediatric patients with HCM are asymptomatic, and there is not a strong correlation between symptoms and the presence or magnitude of LV outflow tract (LVOT) obstruction or the extent of LV hypertrophy. Age and developmental status play an important role in perception of and ability to express symptoms, particularly for preambulatory and/or preverbal patients.</p><p>Presenting symptoms may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain</p><p class="bulletIndent1"><span class="glyph">●</span>Presyncope/syncope</p><p class="bulletIndent1"><span class="glyph">●</span>Palpitations</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure symptoms (eg, poor feeding, failure to thrive, tachypnea, easy fatigability)</p><p class="bulletIndent1"><span class="glyph">●</span>Sudden cardiac arrest/death</p><p></p><p>In a report of 80 children with HCM identified through a population-based cohort study, presenting clinical features that prompted cardiac evaluation included [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac murmur (53 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of HCM (15 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying syndrome (6 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Congestive heart failure (8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Arrhythmic symptoms (2 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonspecific symptoms (16 percent)</p><p></p><p>The signs and symptoms of HCM vary somewhat according to age:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infants &lt;1 year</strong> – An isolated heart murmur is the most common presentation during the first year of life [<a href="#rid18">18,19</a>]. (See <a class="local">'Physical examination'</a> below.)</p><p></p><p class="bulletIndent1">Symptomatic infants typically present with signs and symptoms of heart failure (eg, tachypnea, poor feeding, and poor growth). Patients with Noonan syndrome are more likely to present prior to six months of age (51 percent versus 28 percent of infants with sarcomeric HCM) and more likely to have symptoms of congestive heart failure (24 versus 9 percent of infants with sarcomeric HCM) [<a href="#rid2">2,18,19</a>]. (See  <a class="medical medical_review" href="/z/d/html/14373.html" rel="external">"Heart failure in children: Etiology, clinical manifestations, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Mortality is high among patients diagnosed with HCM during infancy, particularly in those with inborn errors of metabolism (IEM) and malformation syndromes, and is primarily due to heart failure rather than sudden death [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/110392.html" rel="external">"Hypertrophic cardiomyopathy in children: Management and prognosis", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children ≥1 year of age</strong> – Most older children (≥1 year of age) with HCM are asymptomatic [<a href="#rid20">20</a>]; however, children with IEM have a higher rate of presenting with symptomatic heart failure. Among those who come to clinical attention, symptoms may include [<a href="#rid21">21</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abdominal pain, decrease in appetite, or intolerance of feeds</p><p class="bulletIndent2"><span class="glyph">•</span>Dyspnea on exertion</p><p class="bulletIndent2"><span class="glyph">•</span>Fatigue</p><p class="bulletIndent2"><span class="glyph">•</span>Atypical or anginal chest pain </p><p class="bulletIndent2"><span class="glyph">•</span>Presyncope and syncope, particularly during or immediately following exertion</p><p class="bulletIndent2"><span class="glyph">•</span>Palpitations</p><p class="bulletIndent2"><span class="glyph">•</span>Sudden cardiac arrest/death</p><p></p><p>One possible cause for exertional chest pain (angina) in children with HCM is myocardial bridging. (See  <a class="medical medical_review" href="/z/d/html/1499.html" rel="external">"Myocardial bridging of the coronary arteries"</a>.)</p><p class="headingAnchor" id="H737370189"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination in a child with HCM may be normal or may reveal nonspecific abnormalities such as a systolic murmur, fourth heart sound, and/or an LV lift. Many of the classically described physical examination findings in patients with HCM are associated with LVOT obstruction. Persons with minimal or no LVOT obstruction may have normal or nearly normal physical examinations. (See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Physical examination'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Murmurs</strong> – Patients with HCM may develop several types of systolic murmurs, but the two most common are related to LVOT obstruction and mitral regurgitation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>LVOT obstruction, often due to a combination of LV upper septal hypertrophy and systolic anterior motion (SAM) of the mitral valve, results in a harsh crescendo-decrescendo systolic murmur that begins slightly after S1 and is heard best at the apex and lower left sternal border. The murmur may radiate to the axilla and base, but usually not into the neck. Altering preload and afterload can change the intensity of the murmur, which increases during the Valsalva maneuver or standing abruptly, and decreases with hand grip or squatting. (See  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Left lower sternal border'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SAM of the mitral valve or abnormal mitral valve anatomy related to papillary muscle or chordae tendineae abnormalities can lead to impaired leaflet coaptation and mitral regurgitation. This usually results in a posteriorly directed mitral regurgitation jet, which produces a mid-late systolic murmur at the apex. Centrally directed mitral regurgitation, usually associated with primary mitral valve pathology, classically results in a holosystolic murmur heard loudest at the apex that radiates to the axilla. However, if the regurgitant jet is eccentrically directed, the murmur can radiate toward the base of the heart and may be confused with the murmur of LVOT obstruction. (See  <a class="medical medical_review" href="/z/d/html/4947.html" rel="external">"Hypertrophic cardiomyopathy: Morphologic variants and the pathophysiology of left ventricular outflow tract obstruction", section on 'Development of mitral regurgitation'</a> and  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Apex'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other cardiac findings</strong> – A number of other physical findings may be observed in children with HCM, although none is pathognomonic for HCM. These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Third and/or fourth heart sound (S3 or S4). (See  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Third and fourth heart sounds'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Paradoxic splitting of the second heart sound (S2) in patients with severe LVOT obstruction. (See  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Second heart sound'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Brisk and bifid arterial pulses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diffuse LV apical impulse on palpation. (See  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur", section on 'Palpation of the chest'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parasternal lift.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Signs of congestive heart failure, including pulmonary congestion, peripheral edema, and/or elevation of the jugular venous pressure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noncardiac findings</strong> – Dysmorphic features and other noncardiac findings may suggest an underlying syndromic or genetic disorder associated with HCM  (<a class="graphic graphic_table graphicRef107815" href="/z/d/graphic/107815.html" rel="external">table 1</a>) (eg, short stature, hypertelorism, downward eye slant, and low-set ears in Noonan syndrome; limb and gait ataxia in Friedreich ataxia; generalized muscle weakness in Pompe disease). (See  <a class="medical medical_review" href="/z/d/html/5832.html" rel="external">"Causes of short stature", section on 'Noonan syndrome'</a> and  <a class="medical medical_review" href="/z/d/html/6224.html" rel="external">"Friedreich ataxia"</a> and  <a class="medical medical_review" href="/z/d/html/2905.html" rel="external">"Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)"</a>.)</p><p></p><p class="headingAnchor" id="H2255389630"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H397416513"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The signs and symptoms of HCM in children are nonspecific, and, unless there is a positive family history or a commonly associated syndromic disorder, HCM is usually not the initial diagnostic consideration. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>In approximately one-quarter of pediatric patients with HCM, a positive family history can be elicited [<a href="#rid21">21</a>]. Once a family history of HCM has been identified, the diagnostic evaluation usually includes a three-generation pedigree, ECG, and echocardiogram [<a href="#rid22">22</a>]. (See <a class="local">'Evaluation of first-degree relatives'</a> below.)</p><p>In patients without a positive family history or syndromic findings, a diagnosis of HCM may be suspected after an echocardiogram is obtained for evaluation of a heart murmur or other concerning cardiac symptoms. The evaluation of children with heart murmurs and suspected heart disease is reviewed more broadly in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur"</a> and  <a class="medical medical_review" href="/z/d/html/5765.html" rel="external">"Suspected heart disease in infants and children: Criteria for referral"</a>.)</p><p class="headingAnchor" id="H111402768"><span class="h2">Aims of diagnostic testing</span><span class="headingEndMark"> — </span>Diagnostic testing in children with suspected HCM has the following aims:</p><p class="bulletIndent1"><span class="glyph">●</span>Establish the diagnosis of HCM</p><p class="bulletIndent1"><span class="glyph">●</span>Identify the presence or severity of LV outflow tract (LVOT) obstruction</p><p class="bulletIndent1"><span class="glyph">●</span>Identify the presence or severity of mitral regurgitation</p><p class="bulletIndent1"><span class="glyph">●</span>Assess the risk for arrhythmia (both supraventricular and ventricular) and to risk stratify for SCD</p><p class="bulletIndent1"><span class="glyph">●</span>Assess overall LV diastolic and systolic function</p><p class="bulletIndent1"><span class="glyph">●</span>Offer genetic testing and identify other affected family members</p><p></p><p class="headingAnchor" id="H643546650"><span class="h2">Electrocardiography</span><span class="headingEndMark"> — </span>An ECG should be performed in all children when considering a diagnosis of HCM [<a href="#rid22">22</a>]. ECG testing is the most sensitive routinely performed diagnostic test for HCM, but the ECG abnormalities are not specific to HCM and should prompt further diagnostic evaluation, usually with echocardiography.</p><p>The typical ECG findings in a patient with HCM include prominent voltages with localized or diffuse repolarization abnormalities  (<a class="graphic graphic_waveform graphicRef110278" href="/z/d/graphic/110278.html" rel="external">waveform 1</a>). In certain syndromic causes of HCM, such as Pompe disease, the markedly increased voltages can be pathognomonic  (<a class="graphic graphic_waveform graphicRef110279" href="/z/d/graphic/110279.html" rel="external">waveform 2</a>). A more extensive discussion of the usual ECG findings in a patient with HCM is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Electrocardiography'</a>.)</p><p class="headingAnchor" id="H1304118268"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>Comprehensive transthoracic echocardiography with two-dimensional, color Doppler, spectral Doppler, and tissue Doppler imaging should be performed in all patients when considering a diagnosis of HCM [<a href="#rid22">22</a>]. Echocardiography can demonstrate cardiac morphology  (<a class="graphic graphic_diagnosticimage graphicRef110280 graphicRef110312" href="/z/d/graphic/110280.html" rel="external">image 2A-B</a>), systolic and diastolic function, the presence and severity of an LVOT gradient, and the degree of mitral regurgitation  (<a class="graphic graphic_movie graphicRef79426" href="/z/d/graphic/79426.html" rel="external">movie 1</a> and <a class="graphic graphic_movie graphicRef65618" href="/z/d/graphic/65618.html" rel="external">movie 2</a>) [<a href="#rid23">23-28</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>LV hypertrophy</strong> – In pediatric patients, measurements of LV wall thickness must be adjusted for age and body surface area using z-scores (defined as the number of standard deviations from the population mean). According to the Pediatric Cardiomyopathy Registry criteria, HCM is considered if the LV wall thickness z-score is &gt;2 [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Z-scores can be computed by several different methods. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fzscore.chboston.org%2F&amp;token=zbDbbTxDn%2FqSsQYYKwFX0im45Au2CP%2FMrOq%2B5bbR%2F%2FddoKgRkD0Hz7N12LKix5oN&amp;TOPIC_ID=4951" target="_blank">Boston Children’s Hospital z-score system</a> is based on data gathered over a 12-year period from normal children [<a href="#rid29">29</a>]. Other online calculators are also available [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1">In older adolescents and adults, a clinical diagnosis of HCM is confirmed when LV wall thickness ≥15 mm is imaged anywhere in the LV wall (measured at the thickest segment). A wall thickness of ≥13 mm may also be considered diagnostic of HCM, particularly when identified in a patient whose family member also has HCM.</p><p></p><p class="bulletIndent1">Patients with inborn errors of metabolism and neuromuscular disorders tend to have concentric hypertrophy, whereas those with sarcomeric HCM more commonly have asymmetric septal hypertrophy, but this is not always the case  (<a class="graphic graphic_diagnosticimage graphicRef110280 graphicRef110312" href="/z/d/graphic/110280.html" rel="external">image 2A-B</a>) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systolic anterior motion of the mitral valve</strong> – Pediatric patients with HCM may have systolic anterior motion (SAM) of the mitral valve, which positions the mitral valve within the LVOT. SAM of the mitral valve may result in LVOT obstruction when there is contact between the mitral valve and the septum. The greater the duration of mitral-septal contact, the higher the LVOT obstruction. The presence of SAM is not a requirement for a diagnosis of HCM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LVOT obstruction</strong> – LVOT obstruction is present in 20 to 50 percent of pediatric patients with HCM [<a href="#rid18">18,31</a>]. Echocardiography can be used to accurately and noninvasively measure the presence and magnitude of LVOT gradients using continuous-wave Doppler techniques. LVOT gradients in HCM are dynamic, characterized by spontaneous variability on a day-to-day (or even hourly) basis, and are influenced by factors that alter myocardial contractility and loading conditions (eg, dehydration, heavy meals, etc). Therefore, for patients with no LVOT obstruction at rest who are old enough to cooperate with exercise testing, exercise stress echocardiography should be performed to assess for inducible LVOT obstruction. Performing a Valsalva maneuver (if the child is able to cooperate with the instructions) can also elicit a gradient across the LVOT and may assist with the diagnosis, particularly if exercise testing is not feasible.</p><p></p><p class="headingAnchor" id="H1905951551"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>We offer genetic testing to all patients with HCM, unless there is clinical suspicion for a secondary cause of LV hypertrophy (eg, hypertension). In most cases, referral to a clinical geneticist is warranted to guide the evaluation.</p><p>Genetic testing serves the following purposes:</p><p class="bulletIndent1"><span class="glyph">●</span>It informs testing of other family members ("cascade testing"). (See <a class="local">'Evaluation of first-degree relatives'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with syndromic HCM, characterizing the underlying syndrome can help identify noncardiac issues. If the child has clinical features suggestive of a specific syndromic cause of HCM (eg, Noonan syndrome, glycogen storage disease, mucopolysaccharidosis)  (<a class="graphic graphic_table graphicRef107815" href="/z/d/graphic/107815.html" rel="external">table 1</a>), focused genetic testing for the specific disorder(s) is performed. All infants and young children (ie, &lt;2 to 3 years old) with HCM should be referred to a clinical geneticist for consideration of metabolic or storage disorders since these can be easy to miss. (See  <a class="medical medical_review" href="/z/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing can also aid in the diagnosis of sarcomeric HCM; however, 30 to 50 percent of children with phenotypically-determined HCM do not have identified mutations [<a href="#rid8">8,10-12</a>]. (See <a class="local">'Genetics'</a> above and <a class="local">'Diagnosis'</a> below.)</p><p></p><p>Genetic testing has little prognostic value because there is a substantial amount of genetic heterogeneity and it is not possible to classify mutations as being definitively "benign" or "malignant" [<a href="#rid32">32</a>]. Identifying patients with multiple mutations may have prognostic implications; however, this remains uncertain. (See  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing", section on 'Predicting prognosis with mutations'</a>.)</p><p class="headingAnchor" id="H2423987967"><span class="h2">Additional testing</span><span class="headingEndMark"> — </span>Additional testing may be warranted for diagnostic purposes (eg, if the diagnosis of HCM remains uncertain following echocardiography) and for prognostic purposes (eg, assessment of exercise tolerance, risk assessment for ventricular arrhythmias with ambulatory ECG monitoring). The age and developmental level of the patient are key factors to consider when pursuing additional testing (ie, the child's ability to cooperate with exercise testing or to tolerate cardiovascular magnetic resonance [CMR] imaging without need for sedation).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ambulatory ECG monitoring</strong> – Ambulatory ECG monitoring should be performed in all pediatric patients diagnosed with HCM as part of the risk assessment for ventricular arrhythmias and SCD [<a href="#rid22">22</a>]. In addition, in patients with palpitations in whom the etiology is uncertain or if there is suspicion for atrial fibrillation/flutter, ambulatory monitoring should also be considered. (See  <a class="medical medical_review" href="/z/d/html/958.html" rel="external">"Ambulatory ECG monitoring"</a> and  <a class="medical medical_review" href="/z/d/html/110392.html" rel="external">"Hypertrophic cardiomyopathy in children: Management and prognosis", section on 'Prevention of sudden cardiac death (ICD placement)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise testing</strong> – For all pediatric patients with known or suspected HCM (based on clinical and imaging findings) who are able to exercise on a treadmill, we proceed with exercise stress testing, usually combined with echocardiography to assess LVOT gradient. In a series of 91 children with HCM (median age 12 years, median LV wall thickness 12 mm) who underwent exercise testing, 40 patients (44 percent) had LVOT gradient &lt;30 mmHg at rest but an inducible LVOT gradient &gt;30 mmHg with exercise [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Exercise testing'</a> and  <a class="medical medical_review" href="/z/d/html/6473.html" rel="external">"Exercise testing in children and adolescents: Principles and clinical application"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular magnetic resonance imaging</strong> – We suggest performing CMR for diagnostic purposes in selected patients in whom the diagnosis of HCM remains uncertain following echocardiography. It is reasonable to consider performing CMR for additional risk stratification purposes in all patients with suspected or diagnosed HCM if expense is not an issue and there are no other contraindications to magnetic resonance imaging. In addition, in patients with HCM being considered for surgical myectomy in whom the mitral valve and papillary muscle anatomy are not well defined with echocardiography, CMR can be performed to aid in preoperative surgical planning.</p><p></p><p class="bulletIndent1">Late gadolinium enhancement (LGE) on CMR reflects fibrosis  (<a class="graphic graphic_diagnosticimage graphicRef110321 graphicRef110322" href="/z/d/graphic/110321.html" rel="external">image 1A-B</a>), and studies in adult patients suggest that LGE is a risk factor for SCD independent of other traditional risk factors. (See  <a class="medical medical_review" href="/z/d/html/4952.html" rel="external">"Hypertrophic cardiomyopathy: Risk stratification for sudden cardiac death", section on 'Risk modifiers'</a>.)</p><p></p><p class="bulletIndent1">Among a cohort of 195 patients ≤21 years of age with HCM (155 with phenotypically-determined HCM and 40 genotype-positive/phenotype-negative [G+ P-] patients) who underwent CMR, LGE was present in 70 of 155 patients (46 percent) with phenotypic HCM, but in none of the G+ P- carriers [<a href="#rid34">34</a>]. Although this represents lower incidence of fibrosis compared with studies in adults with HCM, in a subset of patients with serial imaging, there was evidence of progressive fibrosis over time. In a smaller study of children and adolescents with HCM, diffuse fibrosis on CMR correlated with symptoms and elevated serum B-type natriuretic peptide levels [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1">These data are insufficient to firmly establish LGE as a major risk factor for SCD in pediatric patients with HCM. However, when considered together with the data on LGE in adults with HCM, it is reasonable to consider extensive LGE as a potential risk modifier when assessing the overall SCD risk profile. (See  <a class="medical medical_review" href="/z/d/html/110392.html" rel="external">"Hypertrophic cardiomyopathy in children: Management and prognosis", section on 'Prevention of sudden cardiac death (ICD placement)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac catheterization and biopsy</strong> – Invasive hemodynamic assessment via cardiac catheterization is not regularly required to confirm the diagnosis of HCM, but it may have utility if there is a question of restrictive cardiomyopathy or constrictive pericarditis. Endomyocardial biopsy is not regularly used for diagnosis but may be useful to exclude nonsarcomeric disease (eg, Fabry disease, amyloidosis, Danon disease). (See  <a class="medical medical_review" href="/z/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Cardiac catheterization'</a> and  <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">"Endomyocardial biopsy"</a>.)</p><p></p><p class="headingAnchor" id="H3960121516"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of HCM is established based on echocardiography and/or CMR. The hallmark finding is increased LV wall thickening  (<a class="graphic graphic_diagnosticimage graphicRef110321 graphicRef110322" href="/z/d/graphic/110321.html" rel="external">image 1A-B</a> and <a class="graphic graphic_diagnosticimage graphicRef110280 graphicRef110312" href="/z/d/graphic/110280.html" rel="external">image 2A-B</a>) without an identifiable hemodynamic cause (eg, hypertension, valve disease) [<a href="#rid36">36</a>]. Other findings such as SAM of the mitral valve or hyperdynamic LV support the diagnosis but are not obligatory. (See <a class="local">'Echocardiography'</a> above.)</p><p>Identification of a known pathogenic mutation in the setting of otherwise unexplained LV hypertrophy is diagnostic for HCM; however many children with phenotypically-determined HCM will have no identified mutation. In the case of a patient with no identified mutation or a variant of unknown significance, the diagnosis is based primarily on clinical findings, echocardiography, and family history. (See <a class="local">'Genetic testing'</a> above and  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing"</a>.)</p><p class="headingAnchor" id="H489747930"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heart murmurs </strong>– Physical examination findings can help distinguish HCM from other causes of heart murmurs in children, though ultimately echocardiogram is necessary to confirm or exclude HCM as the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/103723.html" rel="external">"Approach to the infant or child with a cardiac murmur"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest pain, syncope, or symptoms of heart failure </strong>– There are many possible causes of chest pain  (<a class="graphic graphic_table graphicRef96739" href="/z/d/graphic/96739.html" rel="external">table 2</a>), syncope  (<a class="graphic graphic_table graphicRef60014" href="/z/d/graphic/60014.html" rel="external">table 3</a>), and heart failure  (<a class="graphic graphic_table graphicRef79989" href="/z/d/graphic/79989.html" rel="external">table 4</a>) in children, including primary cardiac and noncardiac etiologies. The clinical course, physical examination findings, ECG, and echocardiogram distinguish HCM from other causes. (See  <a class="medical medical_review" href="/z/d/html/6466.html" rel="external">"Causes of syncope in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/96737.html" rel="external">"Causes of nontraumatic chest pain in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/14373.html" rel="external">"Heart failure in children: Etiology, clinical manifestations, and diagnosis", section on 'Etiology and pathophysiology'</a> and  <a class="medical medical_review" href="/z/d/html/5765.html" rel="external">"Suspected heart disease in infants and children: Criteria for referral"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LVH on echocardiogram </strong>– Other causes of LV hypertrophy (LVH) in infants and children include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension. (See  <a class="medical medical_review" href="/z/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Athlete's heart (in adolescents). (See  <a class="medical medical_review" href="/z/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Athlete's heart'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Valvar, subvalvar, or supravalvar aortic stenosis. (See  <a class="medical medical_review" href="/z/d/html/5775.html" rel="external">"Valvar aortic stenosis in children"</a> and  <a class="medical medical_review" href="/z/d/html/5776.html" rel="external">"Subvalvar aortic stenosis (subaortic stenosis)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary parenchymal or vascular disease. (See  <a class="medical medical_review" href="/z/d/html/17234.html" rel="external">"Pulmonary hypertension in children: Classification, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endocrine disease (eg, maternal gestational diabetes). (See  <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)", section on 'Ventricular hypertrophy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rheumatic and immunological disease (eg, systemic lupus erythematosus). (See  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Cardiac'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiotoxic exposures (eg, anthracyclines). (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p></p><p class="bulletIndent1">These other causes of LVH can be distinguished from HCM on the basis of the echocardiogram, clinical history, family history including three-generation pedigree, blood pressure measurements, and metabolic and/or genetic testing. Historical elements such as longstanding hypertension, rheumatological diagnosis, or history of cardiotoxic exposure can implicate secondary LVH over HCM. Family history of suspicious LVH in multiple family members suggests an inherited primary pathologic process. Although no single finding on noninvasive diagnostic testing can distinguish HCM from a secondary cause of LVH (eg, hypertension, athlete's heart), HCM is more likely with lateral ECG changes and echocardiographic findings of nonconcentric LVH, maximal LV wall thickness &gt;15 mm, nondilated LV cavity (LV end-diastolic diameter ≤55 mm), LV outflow tract obstruction at rest, and late gadolinium enhancement patterns on CMR [<a href="#rid37">37</a>].</p><p></p><p class="headingAnchor" id="H1152560368"><span class="h1">EVALUATION OF FIRST-DEGREE RELATIVES</span><span class="headingEndMark"> — </span>Hypertrophic cardiomyopathy is an autosomal dominant disorder, and most mutations have a high degree of penetrance. As a result, first-degree family members of an affected individual should be evaluated for possible inheritance of the disease  (<a class="graphic graphic_algorithm graphicRef126987" href="/z/d/graphic/126987.html" rel="external">algorithm 1</a>). Our approach is as follows, and is generally consistent with the recommendations of a variety of experts and professional societies [<a href="#rid22">22,38</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical evaluation</strong> – First-degree relatives of the proband should undergo screening that includes history, physical examination, ECG, and echocardiography or other appropriate imaging modality. We proceed with screening for all first-degree relatives regardless of age because limited data suggest that HCM may manifest prior to age 10 in approximately 30 percent of patients [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent1">Family members who have a normal clinical evaluation should not necessarily be assumed to be free of risk:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If screening is normal in a child prior to puberty, clinical evaluation should be repeated every two to three years until the onset of puberty.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Because hypertrophy frequently develops during adolescence, clinical evaluation should be repeated annually from 12 to 18 years of age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Due to the possibility of delayed-onset hypertrophy, it is recommended that adult family members with normal ECGs and echocardiograms who are over the age of 18 be reevaluated approximately every three to five years. There may be a role for tissue Doppler echocardiography in such patients, where abnormalities in contraction and relaxation velocities can suggest preclinical myocardial dysfunction [<a href="#rid40">40-42</a>]. However, these abnormalities are not considered diagnostic for HCM and rarely precede the development of ECG abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic testing</strong> – Genetic testing is based on whether an HCM-causing mutation has been identified in the index case:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Index case has an</strong> <strong>HCM-causing variant</strong> – If the index case has a pathogenic or likely pathogenic variant, we proceed with targeted genetic testing in all first-degree relatives of the proband ("cascade testing"). (See  <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">"Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing", section on 'Screening of family members for HCM'</a>.)</p><p></p><p class="bulletIndent2">Relatives who test negative for the mutation are considered unaffected. Relatives testing positive for the same disease-causing mutation as the index case, but in whom there is no clinical evidence of LV hypertrophy (referred to as genotype-positive/phenotype-negative [G+ P-]), are considered at risk for developing HCM and require regular repeated clinical evaluations, as detailed above.</p><p></p><p class="bulletIndent2">In a study of 119 children who were identified through cascade genetic testing to have pathogenic sarcomere mutations and who were followed for an average of 6.9 years, 7 percent developed increased LV wall thickness, consistent with a clinical diagnosis of HCM [<a href="#rid14">14</a>]. In another study of 285 adult and pediatric patients with identified sarcomeric protein mutations, reported penetrance for developing HCM was almost 50 percent at 15 years of follow-up [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2">These studies suggest that some G+ P- individuals may never develop a clinical diagnosis of HCM; however, the incidence is much higher than the general population, and persons with an identified sarcomeric mutation warrant lifelong follow-up. Both points should be raised when discussing genetic testing with families.</p><p></p><p class="bulletIndent2">Another point to make when counseling patients before cascade testing is that results of genetic testing can be accessed by life and disability insurers. However, in the United States and many other countries, it is illegal to discriminate against patients for health insurance based on a preexisting genetic diagnosis. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Genetic discrimination'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Index case does not have an</strong> <strong>HCM-causing variant</strong> – If the index case or relatives do not have a definite HCM-causing mutation, we proceed only with clinical screening and do not perform genetic testing.</p><p></p><p class="headingAnchor" id="H632521952"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115416.html" rel="external">"Society guideline links: Cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H2661568695"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15753.html" rel="external">"Patient education: Hypertrophic cardiomyopathy in adults (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83800.html" rel="external">"Patient education: Hypertrophic cardiomyopathy in children (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3445.html" rel="external">"Patient education: Hypertrophic cardiomyopathy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2330329664"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions and prevalence </strong>– Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy (LVH)  (<a class="graphic graphic_diagnosticimage graphicRef110321 graphicRef110322" href="/z/d/graphic/110321.html" rel="external">image 1A-B</a> and <a class="graphic graphic_diagnosticimage graphicRef110280 graphicRef110312" href="/z/d/graphic/110280.html" rel="external">image 2A-B</a>). The term HCM is applied broadly to a number of different clinical presentations, including sarcomeric HCM as well as HCM occurring as part of a broader genetic syndrome or neuromuscular disorder  (<a class="graphic graphic_table graphicRef107815" href="/z/d/graphic/107815.html" rel="external">table 1</a>). HCM is one of the most common forms of inherited cardiomyopathy, with a prevalence of approximately 0.3 to 0.5 cases per 100,000 children. (See <a class="local">'Definitions'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Clinical findings associated with HCM can develop at any time from infancy to adolescence or early adulthood. Patients who are diagnosed with HCM in infancy are more likely to have a symptoms of heart failure at presentation, while children diagnosed at age ≥1 year of age are most commonly asymptomatic. An isolated heart murmur is another common presenting finding. Other presenting symptoms may include chest pain, presyncope/syncope, palpitations, heart failure symptoms, and/or sudden cardiac arrest/death. The physical examination may be normal or may reveal nonspecific abnormalities such as a systolic murmur, fourth heart sound, and/or a left ventricular (LV) lift. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – When HCM is suspected, the diagnostic evaluation includes (see <a class="local">'Diagnostic evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A three-generation pedigree.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ECG. (See <a class="local">'Electrocardiography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Echocardiogram. (See <a class="local">'Echocardiography'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – We offer genetic testing to all patients with HCM, unless there is clinical suspicion for a secondary cause of LVH (eg, hypertension). In most cases, referral to a clinical geneticist is warranted to guide the evaluation. (See <a class="local">'Genetic testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional selective testing – This may include ambulatory monitoring, exercise testing, cardiac magnetic resonance imaging, and/or cardiac catheterization with endomyocardial biopsy. These tests may be warranted for diagnostic purposes, and for prognostic purposes or risk assessment. (See <a class="local">'Additional testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The hallmark finding of HCM is increased LV wall thickening without an identifiable hemodynamic cause (eg, hypertension, valve disease)  (<a class="graphic graphic_diagnosticimage graphicRef110321 graphicRef110322" href="/z/d/graphic/110321.html" rel="external">image 1A-B</a> and <a class="graphic graphic_diagnosticimage graphicRef110280 graphicRef110312" href="/z/d/graphic/110280.html" rel="external">image 2A-B</a>). Other findings such as systolic anterior motion (SAM) of the mitral valve or hyperdynamic LV support the diagnosis but are not obligatory. Identification of a known pathogenic mutation in the setting of otherwise unexplained LVH is diagnostic for HCM; however, 30 to 50 percent of children with phenotypically-determined HCM will have no identified mutation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of first-degree relatives</strong> – Once the diagnosis of HCM is made, all first-degree relatives of the proband should undergo a clinical evaluation that includes history, physical examination, ECG, and echocardiography. In addition, if a definite HCM-causing mutation has been identified in the index case, we proceed with targeted genetic testing in all first-degree relatives of the proband. (See <a class="local">'Evaluation of first-degree relatives'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of HCM in children is broad and includes other causes of murmurs, chest pain, syncope, and heart failure, including primary cardiac and noncardiac etiologies. The clinical course, physical examination findings, ECG, and echocardiogram distinguish HCM from other causes. Other causes of LVH include hypertension; athlete's heart; valvar, subvalvar or supravalvar aortic stenosis; pulmonary parenchymal or vascular disease; endocrine disease (eg, maternal gestational diabetes); rheumatic and immunological disease (eg, systemic lupus erythematosus); and cardiotoxic exposures (eg, anthracyclines). These other causes of LVH can be distinguished from HCM on the basis of the echocardiogram, clinical history, family history including three-generation pedigree, blood pressure measurements, and metabolic and/or genetic testing. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H908657383"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John L Jefferies, MD, MPH, FACC, FAHA, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat Rev Cardiol 2022; 19:151.</a></li><li><a class="nounderline abstract_t">Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J 2012; 164:442.</a></li><li><a class="nounderline abstract_t">Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115:773.</a></li><li><a class="nounderline abstract_t">Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348:1639.</a></li><li><a class="nounderline abstract_t">Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348:1647.</a></li><li><a class="nounderline abstract_t">Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol 1997; 146:385.</a></li><li><a class="nounderline abstract_t">Veselka J, Anavekar NS, Charron P. Hypertrophic obstructive cardiomyopathy. Lancet 2017; 389:1253.</a></li><li><a class="nounderline abstract_t">Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60:705.</a></li><li><a class="nounderline abstract_t">Edelson JB, Griffis H, Burstein DS, et al. The Impact of Syndromic Genetic Disorders on Medical Management and Mortality in Pediatric Hypertrophic Cardiomyopathy Patients. Pediatr Cardiol 2020; 41:1180.</a></li><li><a class="nounderline abstract_t">Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358:1899.</a></li><li><a class="nounderline abstract_t">Ware SM, Wilkinson JD, Tariq M, et al. Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes Study. J Am Heart Assoc 2021; 10:e017731.</a></li><li><a class="nounderline abstract_t">Norrish G, Cleary A, Field E, et al. Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2022; 79:1986.</a></li><li><a class="nounderline abstract_t">Bos JM, Will ML, Gersh BJ, et al. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2014; 89:727.</a></li><li><a class="nounderline abstract_t">Vermeer AMC, Clur SB, Blom NA, et al. Penetrance of Hypertrophic Cardiomyopathy in Children Who Are Mutation Positive. J Pediatr 2017; 188:91.</a></li><li><a class="nounderline abstract_t">Tadros R, Francis C, Xu X, et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet 2021; 53:128.</a></li><li><a class="nounderline abstract_t">Marstrand P, Han L, Day SM, et al. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation 2020; 141:1371.</a></li><li><a class="nounderline abstract_t">Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. J Am Coll Cardiol 2020; 75:3033.</a></li><li><a class="nounderline abstract_t">Nugent AW, Daubeney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005; 112:1332.</a></li><li><a class="nounderline abstract_t">Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982; 65:7.</a></li><li><a class="nounderline abstract_t">Maurizi N, Passantino S, Spaziani G, et al. Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. JAMA Cardiol 2018; 3:520.</a></li><li class="breakAll">Colan DC. Cardiomyopathies. In: Nadas' Pediatric Cardiology, 2nd Ed, Keane JF, Lock JE, Fyler DC (Eds), Saunders, Philadelphia 2006. p.432.</li><li><a class="nounderline abstract_t">Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142:e558.</a></li><li><a class="nounderline abstract_t">Nishimura RA, Holmes DR Jr. Clinical practice. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350:1320.</a></li><li><a class="nounderline abstract_t">Pollick C, Morgan CD, Gilbert BW, et al. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation 1982; 66:1087.</a></li><li><a class="nounderline abstract_t">Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985; 28:1.</a></li><li><a class="nounderline abstract_t">Maron BJ, Gottdiener JS, Arce J, et al. Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography. J Am Coll Cardiol 1985; 6:1.</a></li><li><a class="nounderline abstract_t">Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:91.</a></li><li><a class="nounderline abstract_t">Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020; 142:e533.</a></li><li class="breakAll">Colan SD. Normal echocardiographic values for cardiovascular structures, Appendix 1. In: Echocardiography in Pediatric and Congenital Heart Disease, Lai WW, Cohen MS, Geva T, Mertens L (Eds), Wiley-Blackwell, West Sussex, UK 2009. p.765.</li><li class="breakAll">Paramater(z) left ventricular wall thickness z-scores. http://www.parameterz.com/ (Accessed on May 19, 2016).</li><li><a class="nounderline abstract_t">Moak JP, Leifer ES, Tripodi D, et al. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. Pediatr Cardiol 2011; 32:1096.</a></li><li><a class="nounderline abstract_t">Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54:201.</a></li><li><a class="nounderline abstract_t">El Assaad I, Gauvreau K, Rizwan R, et al. Value of Exercise Stress Echocardiography in Children with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr 2020; 33:888.</a></li><li><a class="nounderline abstract_t">Axelsson Raja A, Farhad H, Valente AM, et al. Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy. Circulation 2018; 138:782.</a></li><li><a class="nounderline abstract_t">Hussain T, Dragulescu A, Benson L, et al. Quantification and significance of diffuse myocardial fibrosis and diastolic dysfunction in childhood hypertrophic cardiomyopathy. Pediatr Cardiol 2015; 36:970.</a></li><li><a class="nounderline abstract_t">Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med 2018; 379:655.</a></li><li><a class="nounderline abstract_t">Augustine DX, Howard L. Left Ventricular Hypertrophy in Athletes: Differentiating Physiology From Pathology. Curr Treat Options Cardiovasc Med 2018; 20:96.</a></li><li><a class="nounderline abstract_t">Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35:2733.</a></li><li><a class="nounderline abstract_t">Lafreniere-Roula M, Bolkier Y, Zahavich L, et al. Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines? Eur Heart J 2019; 40:3672.</a></li><li><a class="nounderline abstract_t">Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001; 104:128.</a></li><li><a class="nounderline abstract_t">Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002; 105:2992.</a></li><li><a class="nounderline abstract_t">Nagueh SF, McFalls J, Meyer D, et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003; 108:395.</a></li><li><a class="nounderline abstract_t">Lorenzini M, Norrish G, Field E, et al. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J Am Coll Cardiol 2020; 76:550.</a></li></ol></div><div id="topicVersionRevision">Topic 4951 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34526680" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22980313" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261650" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711738" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The epidemiology of childhood cardiomyopathy in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711739" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The incidence of pediatric cardiomyopathy in two regions of the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9290498" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27912983" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hypertrophic obstructive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22796258" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32474737" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Impact of Syndromic Genetic Disorders on Medical Management and Mortality in Pediatric Hypertrophic Cardiomyopathy Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18403758" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Shared genetic causes of cardiac hypertrophy in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33906374" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35589160" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24793961" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28396031" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Penetrance of Hypertrophic Cardiomyopathy in Children Who Are Mutation Positive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33495596" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32228044" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32553256" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116056" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6458422" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypertrophic cardiomyopathy in infants: clinical features and natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710196" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710196" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215931" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15044643" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical practice. Hypertrophic obstructive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7127693" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3160067" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4040139" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dynamic subaortic obstruction in hypertrophic cardiomyopathy: analysis by pulsed Doppler echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1729351" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215938" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215938" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33215938" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21487794" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19589432" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32279939" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Value of Exercise Stress Echocardiography in Children with Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29622585" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605038" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Quantification and significance of diffuse myocardial fibrosis and diastolic dysfunction in childhood hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30110588" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical Course and Management of Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30367318" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Left Ventricular Hypertrophy in Athletes: Differentiating Physiology From Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25173338" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31170284" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11447072" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12081993" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860897" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32731933" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
